jdno Tuesday, 07/18/17 11:46:30 AM Re: None Post # of 388 Also, fwiw, independent biotech analyst Jason Napodano covers HPPI and has written a few reports on the company going back almost a year now. The first 4 or 5 reports used to be on his "free" site www.bionapinc.com. But he's also started a subscription website biotech service (www.bio5c.com) where he covers many, many young biotechs. Just last week he transferred his previously available free reports from his original site over to the subscription site. While I don't subscribe to his www.bio5c.com service (at least, not yet), I have read his original 4 or 5 reports on HPPI and they're high quality and paint a pretty strong outlook for SUBA-itraconazole. He also wrote a new report (ahead of the company receiving FDA feedback in the very near term) on HPPI just last week, but that's on his pay site, so I haven't read that one yet. While HPPI compensates Jason for covering the company and publishing updated reports, I was just happy to finally see this little company get some coverage a year ago. I guess my point of this post is that if someone is looking to read some pretty detailed reports on HPPI and the outlook for the company, one can check out Jason's subscription site now and see 5 or 6 reports on HPPI. Lastly, fwiw, Jason is also a shareholder in the company...he covers a lot of biotechs on his website(s) but isn't a shareholder of all of them. So take that fwiw I suppose. Note, I don't work with Jason or anything, but an underfollowed name like HPPI needs all the help it can get in educating investors about its story and share price potential, assuming the FDA doesn't pull a fast one on the company. If the FDA essentially green lights the company to file for approval in BCCNS on just this single Ph. 2 trial that are in very late stages -- and if the company communicates this fact to the investment community -- then the share price should begin to perform very nicely over the next year or so, imo. If the FDA requires another confirmatory study after this one, then, ughh, smh, I'd rather not think about that.